2 курс / Гистология / Востриков_В_М_Олигодендроглия_в_мозге_человека_при_шизофрении

191

132.Dazzan P., Morgan K.D., Orr K., Hutchinson G., Chitnis X., Suckling J., Fearon P., McGuire P.K., Mallett R.M., Jones P.B., Leff J., Murray R.M. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. // Neuropsychophamiacology, 2005, 30: 765-774.

133.Deadwyler G.D., Pouly S., Antel J.P., Devries G.H. Neuregulins and erbB receptor expression in adult human oligodendrocytes. // Glia, 2000, 32:3,304-312.

134.Dean В., Laws S.M., Hone E., Taddei K., Scarr E., Thomas E.A., Harper C., McClean C, Masters C, Lautenschlager N., Gandy S.E., Martins R.N. Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. // Biol. Psychiatry, 2003, 54: 616-622.

135.DeLisi L.E., Sakuma M., Tew W., Kushner M., Hoff A.L., Grimson R. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. // Psychiatry Res., 1997,74: 129-140.

136.DeLisi L.E., Stritzke P., Riordan H., Holan V., Boccio A., Kushner M., McClelland J., Van Eyl O., Anand A. The timing of brain morphological changes in schizophrenia and their relationship to clinical outcome. //Biol. Psychiatry, 1992, 31: 241-254.

137.Dietrich J., Han R., Yang Y., Mayer-Proschel M., Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. // J. Biol., 2006, 5: 7, 22, doi: 10.1186/jbiol50

138.Do KQ, Trabesinger AH, Kirsten-Kriiger M, Lauer СJ, Dydak U, Hell D, Holsboer F, Boesiger P, Cuenod M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci. 2000,12: 10,3721-3728.

139.Domercq M., Etxebarria E., Perez-Samartin A., Matute C. Excitotoxic oligodendrocyte death and axonal damage induced by grutamate transporter inhibition. // Glia, 2005, 52: 1, 36-46.

192

140.Dong W.K. and Greenough W.T. Plasticity of nonneuronal brain tissue: roles in developmental disorders. // Ment. Retard. Dev. Disabil. Res. Rev., 2004, 10: 2, 85-90.

141.Dougherty K.D., Dreyfus C.F., Black LB. Brain-derived neurotrophic factor in astrocytes, oligodendrocytes, and microglia/macrophages after spinal cord injury. // Neurobiol. Dis., 2000, 7: (6 PtB), 574-585.

142.Dracheva S., Davis K.L., Chin В., Woo D.A., Schmeidler J., Haroutunian V. Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in schizophrenia. // Neurobiology Disease, 2005, 79: 157-173.

143.Drevets W.C. Neuroimaging and neuropathological studies in depression: Implication for the cognitive-emotional features of mood disorders. // Curr.Opin. Neurobiol., 2001, 11: 240-249.

144.Drevets W.C. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. // Prog Brain Res., 2000, 126:413-431.

145.Durany N., Michel Т., Zochling R., Boissl K.W., Cruz-Sanchez F.F., Riederer P., Thome J. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. // Schizophr Res., 2001, 52: 1-2, 79-86.

146.Eastwood S.L., Heffernan J., Harrison P.J. Chronic haloperidol treatment differentially affects the expression of synaptic and neuronal plasticity-associated genes. //Mol. Psychiatry, 1997, 2: 322-329.

147.Esposito P., Gheorghe D., Kandere K., Pang X., Connolly R., Jacobson S., Theoharides T.C. Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. // Brain Res., 2001,888: 1,117-127.

148.Falkai P., Honer W.G., David S., Bogerts В., Majtenyi C, Bayer T.A. No evidence for astrogliosis in brains of schizophrenic patients. A

193

post-mortem study. // Neuropathology Applied Neurobiology, 1999, 25:

48-53.

149.Fendri C, Mechri A, Khiari G, Othman A, Kerkeni A, Gaha L. Oxidative stress involvement in schizophrenia pathophysiology: a review. Encephale. 2006, 32: (2 Pt 1), 244-252.

150.Fields R.D. Myelination: an overlooked mechanism of synaptic plasticity?//Neuroscientist, 1999,2005, 11:6, 528-531.

151.Fischer W., Sirevaag A., Wiegand S.J., Lindsay R.M., Bjorklund A. Reversal of spatial memory impainnents in aged rats by nerve growth factor and neurotrophins 3 and 4/5 but not by brain-derived neurotrophic factor. // Proc Natl Acad Sci U S A, 1994, 91:18, 8607-8611.

152.Flynn S.W., Lang D.J., Mackay A.L., Goghari V., Vavasour I.M., Whittall K.P., Smith G.N., Arango V., Mann J.J., Dwork A.J., Falkai P., Honer W.G. Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post mortem with oligodendrocyte proteins. // Mol. Psychiatry, 2003, 8: 811-820.

153.Foong J., Maier M., Clark C.A., Barker G.J., Miller D.H., Ron M.A. Neuropathological abnormalities of the corpus callosum in schizophrenia: a diffusion tensor imaging study. // J. Neurol. Neurosurg. Psychiatry, 2000,

68:2, 242-244.

154.Franz Т., Waechneltd T.V., Neuhoff V., Wachtler K. Central nervous system myelin proteins and glycoproteins in vertebrates: A phylogenetic study. // Brain Res., 1981, 226: 245-258.

155.Frazier J.A., Giedd J.N., Kaysen D., Albus K., Hamburger S., Alaghband-Rad J., Lenane M.C., McKenna K., Breier A., Rapoport J.L. Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment. //Am. J. Psychiatry, 1996, 153: 564-566.

156.Fuster J.M. Frontal lobe and cognitive development. // J Neurocytol., 2002,31:3-5,373-85.

194

157.Gabbott P.L., Stewart M.G., Rose S.P. The quantitative effects of dark-rearing and light exposure on the laminar composition and depth distribution of neurons and glia in the visual cortex (area 17) of the rat. // Exp. Brain Res., 1986, 64: 1, 225-232.

158.Galagher P., Watson S., Smith M.S., Young A.H., Ferrier I.N. Plasma-cortisol-dehydroepiandrosterone (DHEA) ratios in schizoplirenia and bipolar disorder. // Schizophr. Res., 2007, 90: 258-265.

159.Garcia C.I., Paez P., Soto E.F., Pasquini J.M. Differential effects of apotransferrin on two populations of oligodendroglial cells. // Glia, 2003,

42:406-416.

160.Gardner E.B., Boitano J.J., Mancino N.S., D'Amico D.P. Environment enrichment and deprivation: Effects on learning, memory and exploration. //Physiol. Bechav., 1975, 14: 321-327.

161.Garey L.J., Ong W.Y., Patel T.S., Kanani M., Davis A., Mortimer A.M., Barnes T.R., Hirsch S.R. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. // J. Neurol. Neurosurg. Psychiatry, 1998, 65: 4, 446-453.

162.Garwood J., Garcion E., Dobbertin A., Heck N., Calco V., ffrenchConstant C, Faissner A. The extracellular matrix glycoprotein Tenascin-C is expressed by oligodendrocyte precursor cells and required for the regulation of maturation rate, survival and responsiveness to plateletderived growth factor. // Eur J. Neurosci., 2004, 20: 10, 2524-2540.

163.Ghandour M.S., Langley 0.K,. Zhut X.L, Waheed A., Sly W.S. Carbonic anhydrase IV on brain capillary endothelial cells: A marker associated with the blood-brain barrier. // Proc. Natl. Acad. Sci. USA, 1992, 89: 6823-6827.

164.Givogri M.I., Galbiati F., Fasano S., Amadio S., Perani L., Superchi D., Morana P., Del Cairo U., Marchesini S., Brambilla R., Wrabetz L., Bongarzone E. Oligodendroglial progenitor cell therapy limits central

195

neurological deficits in mice with metachromatic leukodystrophy. // J.

Neurosci., 2006, 26: 3109-3119.

165.Glantz L.A. and Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. // Arch. Gen. Psychiatry, 2000, 57: 1, 65-73.

166.Goldbaum O. and Richter-Landsberg C. Stress proteins in

oligodendrogliocytes: differential effects of heat shock and oxidative stress.

//J. Neurochem., 2001, 78: 1233-1242.

167.Gonul A.S., Kitis O., Ozan E., Akdeniz F., Eker C, Eker O.D., Vahip S. The effect of antidepressant treatment on N-acetyl aspartate levels of medial frontal cortex in drag-free depressed patients. // Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30: 1, 120-125.

168.Gould E., Beylin A., Tanapat P., Reeves A., Shors T.J. Learning enhances adult neurogenesis in the hippocampal formation. // Nature Neurosci., 1999, 2: 3, 260-265.

169.Gundersen H.J.G. and Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. // J. Microsc, 1987, 147: 229-

170.Gundersen H.J.G., Bagger P., Bendtsen T.F., Evans S.M., Korbo L., Marcussen N., Moller A., Neilsen K., Nyengaard J.R., Pakkenberg В., Sorensen F.B., Vesterby A., West MJ. The new stereological tools: Disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. // Acta Pathol. Microbiol. Immunol. Scand., 1988,96:857-881.

171.Gur R.E., Cowell P., Turetsky B.I., Gallacher F., Cannon Т., Bilker W., Gur R.C. A follow-up magnetic resonance imaging study of schizophrenia: relationship of Neuroanatomical changes to clinical and neurobehavioral measures. //Arch. Gen. Psychiatry, 1998, 55: 145-152.

196

172.Gur R.E., Maany V., Mozley P.D., Swanson C., Bilker W., Gur R.C: Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. //Am. J. Psychiatiy, 1998, 155: 1711-1717.

173.Hagihara K, Miura R, Kosaki R, Berglund E, Ranscht B, Yamaguchi Y. Immunohistochemical evidence for the brevican-tenascin-R interaction: colocalization in perineuronal nets suggests a physiological role for the interaction in the adult rat brain. J Comp Neurol. 1999, 410: 2, 256-64.

174.Hakak Y., Walker J.R., Wong W.R., Davis K.L., Buxbaum J.D., Haroutunian V., Feinberg A.A. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. // Proc. Natl. Acad. Sci. USA, 2001, 98: 4746-4751.

175.Hamidi M., Drevets W.C., Price J.L. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. // Biol. Pstchiatry, 2004,55:663-569.

176.Haorah J., Ramirez S.H., Schall K., Smith D., Pandya R., Persidsky

Y. Oxidative stress activates protein tyrosine kinase and matrix

metalloproteinases leading to blood-brain barrier dysfunction. // J.

Neurochem., 2007, 101: 566-576.

177.Harrison P.J., Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. // Mol. Psychiatry, 2005, 10: 40-68.

178.Harrison P.J. Effects of neuroleptics on neuronal and synaptic structure. / In: Barnes TRE, editor. Antipsychotic drugs and their sideeffects. London: Academic Press, 1993. p. 99-11.

179.Hashimoto Т., Bergen S.E., Nguyen Q.L., Xu В., Monteggia L.M., Pierri J.N., Sun Z., Sampson A.R., Lewis D.A. Relationship of brainderived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. // J. Neurosci., 2005, 25: 2, 372-383.

180.Haydon P.G. Glia: listening and talking to the synapse. // Neuroscience,2001,2: 185-193.

197

181.Hirayasu Y., Tanaka S., Shenton M.E., Salisbury D.F., DeSantis M.A., Levitt J.J., Wible C, Yurgelun-Todd D., Kikinis R., Jolesz F.A,. McCarley R.W. Prefrontal gray matter volume reduction in first episode schizophrenia. // Cereb. Cortex, 2001, 11: 374-381.

182.Ho B.C., Andreasen N.C., Nopoulos P., Arndt S., Magnotta V., Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. // Arch. Gen. Psychiatry, 2003, 60: 585-594.

183.Hof P.R., Haroutunian V., Copland C, Davis K.L., Buxbaum J.D. Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia. //Neurochem. Res., 2002, 27: 1193-1200.

184.Hof P.R., Haroutunian V., Friedrich V. L., Byne W., Buitron C, Perl D.P., Davis K.L. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. // Biol. Psychiatry, 2003, 53: 1075-1085.

185.Hollensworth S.B., Shen C, Sim J.E., Spitz D.R., Wilson G.L., LeDoux S.P. Glial cell type-specific responses to menadione-induced oxidative stress. // Free Radic. Biol. Med., 2000, 28: 1161-1174.

186.Honer W.G., Falkai P., Chen C, Arango V., Mann JJ., Dwork A.J. Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness. //Neuroscience, 1999, 91: 1247-1255.

187.Horrobin D.F. The membrane phosholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. // Schizophr. Res., 1998,30: 1193-208.

188.Hu C.Y., Ong W.Y., Sundaram R.K., Chan C, Patel S.C. Immunocytochemical localization of apolipoprotein D in oligodendrocyte precursor-like cells, perivascular cells, and pericytes in the human cerebral cortex. // J. Neurocytol., 2001, 30: 209-218.

189.Inagawa K., Watanabe S., Tsukada Y., Mikoshiba K. The role of myelination in learning performance observed in two strains of myelin-

198

deficient mutant mice (shiverer and mid). // Behav. Neural. Biol., 1988, 50:

2, 184-192.

190.Iwamoto K., Bundo ML, Yamada К., Takao H., Iwayama-Shigeno Y., Yoshikawa Т., Kato T. DNA methylation status of SOX10 correlates with its downregulation and oligodendrocyte dysfunction in schizophrenia. //J. Neuroscience, 2005, 25: 5376-5381.

191.Jamin N., Junier M.P., Grannec G. Cadusseau J. Two temporal stages of oligodendroglial response to excitotoxic lesion in the gray matter of the adult rat brain. // Exp. Neurol., 2001, 172: 17-28.

192.Jarskog L.F., Selinger E.S., Lieberman J.A., Gilmore J.H. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. // Am. J. Psychiatry, 2004, 161: 109-115.

193.Jarskog L.F. Apoptosis in schizophrenia: pathophysiologic and therapeutic considerations. // Curr. Opin. Psychiatry, 2006, 19: 3, 307-312.

194.Jayakumar P.N., Venkatasubramanian G., Gangadhar B.N., Janakiramaiah N., Keshavan M.S. Optimized voxel-based morphometry of gray matter volume in first-episode, antipsychotic-naive schizophrenia. // Prog Neuropsychopharmacol Biol Psychiatry. 2005, 29: 4, 587-591.

195.Jelinski S.E., Yager J.Y. Juurlink B.H. Preferential injury of oligodendroglioblasts by a short hypoxic-ischemic insult. // Brain Res., 1999,815: 150-153.

196.Jellinger K. Neuromorphological background of pathochemical studies in major psychoses. / In: H. Beckmann and P. Riederer, editors. Pathochemical markers in major psychoses. Berlin: Springer; 1985. p. 1- 23.

197.Jernigan T.L., Trauner D.A., Hesselink J.R., Tallal P.A. Maturation of human cerebrum observed in vivo during adolescence. // Brain, 1991, 114:2037-2049.

199

198.Johnstone E.C., Crow T.J., Frith CD., Husband J., Kreel L. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. // Lancet, 1976,2:924-926.

199.Johnstone-Wilson N., Sims S.D., Hofmann J.P., Anderson L., Shore A.D., Torrey E.F., Yolken R. Disease-specific alteration in frontal cortex brain proteins in schizophrenia, bipolar disorder and major depressive disorder. // Mol. Psychiatry, 2000, 5: 142-149.

200.Kalus P., Muller T.J., Zuschratter W., Senitz D. The dendritic architecture of prefrontal pyramidal neurons in schizophrenic patients. // Neuroreport, 2000, 11: 3621-3625.

201.Kamada H., Yu F., Nito C, Chan P.H. Influence of hyperglycemia on oxidative stress and matrix metalloproteinase-9 activation after focal cerebral ischemia/reperfusion in rats: relation to blood-brain barrier dysfunction. // Stroke, 2007, 38: 1044-1049.

202.Kanaan R.A., Kim J.S., Kaufmann W.E., Pearlson G.D., Barker G.J., McGuire P.K. Diffusion tensor imaging in schizophrenia. // Biol. Psychiatry, 2005, 58: 921-929.

203.Kaplan M.R., Meyer-Franke A., Lambert S., Bennett V., Duncan I.D., Levinson S..R., Barres B.A. Induction of sodium channel clustering by oligodendrocytes. //Nature, 1997, 386: 724-728.

204.Karege F., Bondolfi G., Gervasoni N., Schwald M., Aubry J.M., Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. // Biol Psychiatry, 2005, 57: 9, 1068-1072.

205.Katsel P., Davis K.L., Gorman J.M., Haroutunian V. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions: a gene ontology study. // Schizophr. Res., 2005, 17: 241-252.

206.Katz H.B., Davies C.A. Effects of differential environments on the cerebral anatomy of rats as a function of previous and subsequent housing conditions. //Exp Neurol., 1984, 83: 2, 274-287.

200

207.Kelley J.J., Gao X.M., Tamminga C.A., Roberts R.C. The effect of chronic haloperidol treatment on dendritic spines in the rat striatum. // Exp. Neurol., 1997, 146: 471^178.

208.Kemper T. Neuroanatomical and neuropathological changes during aging and dementia. / In: Albert M., Knoefel J. (Eds.) Clinical neurology of aging, 2nd ed. Oxford University Press, New York, 1994, pp. 3-67.

209.Kempermann G., Kuhn H.G., Gage F.H. More hippocampal neurons in adult mice living in an enriched environment. // Nature, 1997, 386: 493-

210.Kim G.W., Gasche Y., Grzeschik S., Copin J.C., Maier СМ., Chan P.H. Neurodegeneration in striatum induced by the mitochondrial toxin 3- nitropropionic acid: role of matrix metalloproteinase-9 in early blood-brain barrier disruption? // J. Neurosci., 2003, 23: 8733-8742.

211.Kippin Т.Е., Kapur S., van der Kooy D. Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs. // J. Neurosci., 2005, 25: 5815-5823.

212.Klingberg Т., Vaidya C.J., Gabrieli J.D., Moseley M.E., Hedehus M. Myelination and organization of the frontal white matter in children: a diffusion tensor MRI study. //Neuroreport, 1999, 10: 13, 2817-2821.

213.Knable MB, Barci BM, Bartko Л, Webster MJ, Torrey EF. Molecular abnormalities in the major psychiatric illnesses: Classification and Regression Tree (CART) analysis of post-mortem prefrontal markers.

//Mol Psychiatry 2002, 7: 4, 392-404.

214.Kodama M., Fujioka Т., Duman R.S. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. // Biol. Psychiatry, 2004, 56: 570-580.

215. Konopaske G.T., Dorph-Petersen K-A., Sweet R.A., Pierri J.N., Zhang W., Sampson A.R, Lewis D.A. Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. //Biol Psychiatry, doi:10.1016/j.biopsych. 2007.08.018